Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.
about
Systematic review of influenza resistance to the neuraminidase inhibitorsInfluenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistanceResistance to anti-influenza drugs: adamantanes and neuraminidase inhibitorsNeuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cellsStructural and Functional Basis of Resistance to Neuraminidase Inhibitors of Influenza B VirusesH1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural AnalysisStructural and Functional Analysis of Laninamivir and its Octanoate Prodrug Reveals Group Specific Mechanisms for Influenza NA InhibitionComparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Quantitative predictions of binding free energy changes in drug-resistant influenza neuraminidaseUnique Determinants of Neuraminidase Inhibitor Resistance among N3, N7, and N9 Avian Influenza Viruses.Natural variation can significantly alter the sensitivity of influenza A (H5N1) viruses to oseltamivir.From neuraminidase inhibitors to conjugates: a step towards better anti-influenza drugs?Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo.The role of oseltamivir in the treatment and prevention of influenza in children.Computational studies of H5N1 influenza virus resistance to oseltamivir.Assessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assays.Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitorsPeramivir for the treatment of influenza.In vitro passaging of a pandemic H1N1/09 virus selects for viruses with neuraminidase mutations conferring high-level resistance to oseltamivir and peramivir, but not to zanamivir.Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitorsEnzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir.A genetically engineered waterfowl influenza virus with a deletion in the stalk of the neuraminidase has increased virulence for chickens.Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza virusesCharacterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.Single-domain antibodies targeting neuraminidase protect against an H5N1 influenza virus challenge.Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model.Phenotypic and genotypic characterization of influenza virus mutants selected with the sialidase fusion protein DAS181.Determination of neuraminidase kinetic constants using whole influenza virus preparations and correction for spectroscopic interference by a fluorogenic substrateCombinatorial effect of two framework mutations (E119V and I222L) in the neuraminidase active site of H3N2 influenza virus on resistance to oseltamivirStructural analysis of the novel influenza A (H7N9) viral Neuraminidase interactions with current approved neuraminidase inhibitors Oseltamivir, Zanamivir, and Peramivir in the presence of mutation R289KIn silico modification of oseltamivir as neuraminidase inhibitor of influenza A virus subtype H1N1.Repurposing Kinase Inhibitors as Antiviral Agents to Control Influenza A Virus Replication.Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008.Resistance to neuraminidase inhibitors conferred by an R292K mutation in a human influenza virus H7N9 isolate can be masked by a mixed R/K viral population.Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for miceComplete Genome Sequences of an H5N1 Highly Pathogenic Avian Influenza Virus Isolated from Pigeon in China in 2012In vitro generation of neuraminidase inhibitor resistance in A(H5N1) influenza viruses.Influenza reverse genetics: dissecting immunity and pathogenesis.Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms.Ultrasensitive Fluorogenic Reagents for Neuraminidase Titration.
P2860
Q21261835-10FD07A9-05AE-451B-8588-5BA0E9BF3FADQ21562135-4C97579A-A362-4DA0-9260-FB1A6B51B39BQ22305941-3A718719-C798-4EB9-8293-9885A480D439Q24559989-878F652B-5A74-4DAC-9179-285E20147DA9Q27663966-CED39677-1495-4CD6-97C5-9E6167E9BE1FQ27673887-1FA43DB8-096C-43EC-A71D-C503CCC50E66Q27675230-AC6D406D-6EAE-4F80-8559-D488D1130FE8Q28364114-15BDDFF1-6A57-497A-B514-1C75F7394269Q28483033-B3252831-6CEE-483A-AC49-E3C0594D602DQ30202859-C130D2E1-5E37-465C-BB8D-95F5BFB245B4Q30356532-298C8738-A823-4683-975A-E68D58BE7876Q30363724-181E05D2-089E-45A8-9135-848DE44D75F3Q30364619-F361018B-D03D-4024-A676-F354DCBEB01BQ30364977-D913E5B6-8558-44DE-B46F-BAD52C5B0A2FQ30375729-62B9C3F7-9FB0-41F6-AEC3-CF946B84E790Q30390818-8361CD16-ECF8-4A0C-B007-E6CE157E34D6Q30397253-078C668C-3D89-448E-9B05-248B053591F6Q30413154-B93FFB6A-0688-4145-A7B8-79AFD726BD1CQ30416440-8728C00A-F7FF-4818-B41D-0E5568ABC222Q30450742-14846BA9-87F7-43D0-B59A-38D6BBD8ED9FQ33354941-B406F9E5-5F1B-4C37-A9D6-6EEF92AA7E3EQ33558443-F39ABD0F-2DBF-4907-8BBE-8101830B902EQ33999885-69BA9EEA-4183-418F-958D-A24C5054350AQ34057596-CC7F12D1-B821-417D-97FF-22654145C7AFQ34057785-1015082C-88F7-4781-9C93-9A86FCA5B02CQ34120005-9E4FC8B1-9214-4D6F-88E9-06F3E6469894Q34405859-9A6DFA75-AFDB-4881-A263-E82BF814E33DQ34971083-BFB06170-4280-4721-81AA-59D6D7F4283BQ35005209-E2003B6D-0A63-4D7B-8629-EAC22071E9D9Q35101694-FE58974B-EAB7-4081-8DCF-5CDE6A203C83Q35310313-26E57DE7-51F4-4DC4-A939-1A6E4F75FBD5Q35698322-5CEE0667-8639-44D1-8829-53384B13BFD5Q36870919-F759D3C1-683D-4C8D-B61A-F1C836C851E1Q37074496-B663D814-BAD5-42A8-B844-CE165840F476Q37157266-F5C46EE9-E780-44D8-9C33-94DC722176FEQ37209238-A32CDADA-7D5A-4281-A44D-A02E5338AABCQ37392896-5216A7AD-896A-47AB-8BD9-3D7940EF0623Q38188084-CC8DF714-9276-4866-B6B9-BD17B3A8323EQ40138039-41B1BA7E-5027-4A72-ACCB-4B926977C5D6Q40335210-2836B712-5172-4DB7-9F72-FCB1CF51B5F7
P2860
Mechanism by which mutations at his274 alter sensitivity of influenza a virus n1 neuraminidase to oseltamivir carboxylate and zanamivir.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Mechanism by which mutations a ...... vir carboxylate and zanamivir.
@en
Mechanism by which mutations a ...... vir carboxylate and zanamivir.
@nl
type
label
Mechanism by which mutations a ...... vir carboxylate and zanamivir.
@en
Mechanism by which mutations a ...... vir carboxylate and zanamivir.
@nl
prefLabel
Mechanism by which mutations a ...... vir carboxylate and zanamivir.
@en
Mechanism by which mutations a ...... vir carboxylate and zanamivir.
@nl
P2093
P2860
P1476
Mechanism by which mutations a ...... vir carboxylate and zanamivir.
@en
P2093
Chun Y Tai
Dirk B Mendel
Michael Z Wang
P2860
P304
P356
10.1128/AAC.46.12.3809-3816.2002
P407
P577
2002-12-01T00:00:00Z